Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Milojkovic D, Reynolds CJ, Sandoval DM, Pieper FP, Liu S, Pade C, Gibbons JM, McKnight Á, Loaiza S, Palanicawander R, Innes AJ, Claudiani S, Apperley JF, Altmann DM, Boyton RJ. Milojkovic D, et al. Among authors: claudiani s. Leukemia. 2023 Jan;37(1):244-247. doi: 10.1038/s41375-022-01787-8. Epub 2022 Dec 17. Leukemia. 2023. PMID: 36528708 Free PMC article. No abstract available.
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.
Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D. Claudiani S, et al. Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11. Haematologica. 2017. PMID: 28495914 Free PMC article. No abstract available.
The argument for using imatinib in CML.
Claudiani S, Apperley JF. Claudiani S, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504305 Free PMC article. Review.
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF. Nteliopoulos G, et al. Among authors: claudiani s. Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9. Haematologica. 2019. PMID: 31073075 Free PMC article.
30 results